Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials

Claudia Cosentino; Ilaria Dicembrini; Besmir Nreu; Edoardo Mannucci; Matteo Monami

doi:10.1016/j.diabres.2019.107808

Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials

Diabetes Res Clin Pract. 2019 Sep:155:107808. doi: 10.1016/j.diabres.2019.107808. Epub 2019 Aug 8.

Authors

Claudia Cosentino¹, Ilaria Dicembrini¹, Besmir Nreu¹, Edoardo Mannucci¹, Matteo Monami²

Affiliations

¹ Diabetology, Careggi Hospital and University of Florence, Italy.
² Diabetology, Careggi Hospital and University of Florence, Italy. Electronic address: matteo.monami@unifi.it.

PMID: 31401152
DOI: 10.1016/j.diabres.2019.107808

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.

Keywords: Hyperuricemia; Meta-analysis; Nephrolithiasis; SGLT-2 inhibitors.

Publication types

Meta-Analysis

MeSH terms

Humans
Nephrolithiasis / drug therapy*
Nephrolithiasis / pathology
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors / pharmacology
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Sodium-Glucose Transporter 2 Inhibitors